MiR-205 As a Promising Biomarker in the Diagnosis and Prognosis of Lung Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 2

PMID 29190887

Citations 15

Authors

Jing-Hua Li

Shan-Shan Sun

Ning Li

Peng Lv

Shu-Yang Xie

Ping-Yu Wang

Affiliations

Soon will be listed here.

Abstract

MicroRNA-205 (miR-205) was revealed as a novel diagnostic and prognostic biomarker for lung cancer, but the results in the published papers were inconsistent. This meta-analysis aimed to investigate the diagnostic and prognostic roles of miR-205 in patients with lung cancer. Totally, 16 eligible articles were included, among which 10 articles investigated the diagnostic value of miR-205, 5 articles examined its prognostic values, and 1 article studied both diagnostic and prognostic values. For the diagnostic meta-analysis, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the overall area under the curve of miR-205 for patients with lung cancer were 0.88 (95% = 0.78 - 0.94), 0.78 (95% = 0.66 - 0.86), 4.00 (95% = 2.47 - 6.49), 0.16 (95% = 0.08 - 0.30), 25.86 (95% = 9.29 - 71.95), and 0.90 (95% = 0.87 - 0.92), respectively, indicating that miR-205 is a useful biomarker for diagnostic of lung cancer. The subgroup analysis further demonstrated that miR-205 had an excellent overall accuracy for detection with tissue samples compare with blood samples. For the prognostic meta-analysis, the pooled outcome of the disease-free survival and recurrence-free survival analyses revealed that increased miR-205 levels had a protective role in the prognosis of patients with lung cancer (pooled HR = 0.86, 95% CI: 0.78-0.96, z = 2.83, = 0.005). In conclusion, miR-205 may be a promising biomarker for detection, predicting the recurrence of patients with lung cancer.

Citing Articles

The use of biomarkers in the diagnosis of lung cancer.

Mlika M, Mezni F Tunis Med. 2024; 101(4):398-403.

PMID: 38372537 PMC: 11217978.

Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer.

Pirlog R, Chiroi P, Rusu I, Jurj A, Budisan L, Pop-Bica C Int J Mol Sci. 2022; 23(10).

PMID: 35628157 PMC: 9140615. DOI: 10.3390/ijms23105346.

MiRNome analysis identifying miR-205 and miR-449a as biomarkers of disease progression in intestinal-type sinonasal adenocarcinoma.

Re M, Tomasetti M, Monaco F, Amati M, Rubini C, Sollini G Head Neck. 2021; 44(1):18-33.

PMID: 34647653 PMC: 9292973. DOI: 10.1002/hed.26894.

MicroRNA as a Novel Biomarker in the Diagnosis of Head and Neck Cancer.

Kabzinski J, Maczynska M, Majsterek I Biomolecules. 2021; 11(6).

PMID: 34198889 PMC: 8228566. DOI: 10.3390/biom11060844.

Plasma Extracellular Vesicle miRNAs Can Identify Lung Cancer, Current Smoking Status, and Stable COPD.

OFarrell H, Bowman R, Fong K, Yang I Int J Mol Sci. 2021; 22(11).

PMID: 34071592 PMC: 8198071. DOI: 10.3390/ijms22115803.

References

Larzabal L, de Aberasturi A, Redrado M, Rueda P, Rodriguez M, Bodegas M . TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis. Br J Cancer. 2014; 110(3):764-74. PMC: 3915125. DOI: 10.1038/bjc.2013.761. View

Aushev V, Zborovskaya I, Laktionov K, Girard N, Cros M, Herceg Z . Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One. 2013; 8(10):e78649. PMC: 3793941. DOI: 10.1371/journal.pone.0078649. View

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Visone R, Croce C . MiRNAs and cancer. Am J Pathol. 2009; 174(4):1131-8. PMC: 2671346. DOI: 10.2353/ajpath.2009.080794. View

Yang J, Zhang J, Chen J, Xu Y, Song N, Yin C . Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies. PLoS One. 2014; 9(1):e87606. PMC: 3903772. DOI: 10.1371/journal.pone.0087606. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Jemal A, Ma J, Rosenberg P, Siegel R, Anderson W . Increasing lung cancer death rates among young women in southern and midwestern States. J Clin Oncol. 2012; 30(22):2739-44. PMC: 3402885. DOI: 10.1200/JCO.2012.42.6098. View

Liu H, Park J, Manning C, Goehlmann H, Marshall D . Metastatic signature in lung cancer is associated with sensitivity to anti-integrin α(V) monoclonal antibody intetumumab. Genes Chromosomes Cancer. 2014; 53(4):349-57. DOI: 10.1002/gcc.22145. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Response to: Practical methods for incorporating summary time-to-event data into meta. Authors' reply. Trials. 2014; 14:391. View

10.

Miller Y . Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol. 2005; 33(3):216-23. PMC: 2715312. DOI: 10.1165/rcmb.2005-0158OE. View

11.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

12.

Yang J, Zhu J, Zhang Y, Chen Y, Ding L, Kensler T . Lung Cancer in a Rural Area of China: Rapid Rise in Incidence and Poor Improvement in Survival. Asian Pac J Cancer Prev. 2015; 16(16):7295-302. DOI: 10.7314/apjcp.2015.16.16.7295. View

13.

Bai J, Zhu X, Ma J, Wang W . miR-205 regulates A549 cells proliferation by targeting PTEN. Int J Clin Exp Pathol. 2015; 8(2):1175-83. PMC: 4396313. View

14.

Lei L, Huang Y, Gong W . miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep. 2013; 30(6):2897-902. DOI: 10.3892/or.2013.2755. View

15.

Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E . miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol. 2011; 35(2):268-75. DOI: 10.1097/PAS.0b013e3182068171. View

16.

Lu Y, Govindan R, Wang L, Liu P, Goodgame B, Wen W . MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012; 33(5):1046-54. PMC: 3334512. DOI: 10.1093/carcin/bgs100. View

17.

Manegold C . Treatment algorithm in 2014 for advanced non-small cell lung cancer: therapy selection by tumour histology and molecular biology. Adv Med Sci. 2014; 59(2):308-13. DOI: 10.1016/j.advms.2014.08.008. View

18.

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

19.

He H, Han Z, Dai Q, Ling X, Fu X, Lin Z . Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients. BMC Genomics. 2013; 14:757. PMC: 4008360. DOI: 10.1186/1471-2164-14-757. View

20.

Gautam A, Kumar R, Dimitrov G, Hoke A, Hammamieh R, Jett M . Identification of extracellular miRNA in archived serum samples by next-generation sequencing from RNA extracted using multiple methods. Mol Biol Rep. 2016; 43(10):1165-78. PMC: 5025515. DOI: 10.1007/s11033-016-4043-6. View